Clinical trials: Pediatric Population
Pharyngitis
Pharyngitis,Group A Streptococcal Infection,Rapid Streptococcal Test,Throat Swab Culture
Comparison of Immunochromatographic Test for rapid detection of group A streptococcal antigen with culture in Pediatric patients.
- Trial name
- NCT02494219
- Testing
- Rapid Immunochromatographic streptococcal test
- Where
- Qatar
- Volunteers
- 906 people
- Sponsor
- Hamad Medical Corporation
Cataracts, Inflammation
Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery
The primary objective of this study was to compare the safety and efficacy of Durezol™ compared to Pred Forte™ for the treatment of inflammation following cataract surgery in a pediatric population 0 to 3 years of age.
- Trial name
- NCT01124045
- Testing
- Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Alcon Research
Gastrointestinal Diseases, Feeding Intolerance
Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population
The objective of this study is to determine the safe use and tolerance of a peptide-based formula in children with gastrointestinal dysfunction and/or feeding intolerance.
- Trial name
- NCT01191112
- Testing
- Peptide based enteral formula
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- Abbott Nutrition
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric…
- Trial name
- NCT03958877
- Testing
- BIIB017 (peginterferon beta-1a), Interferon beta type 1a
- Where
- 65 sites in United States, Argentina and 20 more
- Volunteers
- 152 people
- Sponsor
- Biogen
Bipolar I Depression
Lurasidone Pediatric Bipolar Study
A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression
- Trial name
- Illuminate (NCT02046369)
- Testing
- Lurasidone
- Where
- 66 sites in United States, Bulgaria and 9 more
- Volunteers
- 350 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis, Allergic, Perennial
Seasonal Allergic Rhinitis In Pediatric Subjects
The purpose of this study is to determine if the investigational drug is effective and safe in children with seasonal allergic rhinitis.
- Trial name
- NCT00107757
- Testing
- GW685698X
- Where
- 65 sites in United States
- Volunteers
- 576 people
- Sponsor
- GlaxoSmithKline
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study
This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease…
- Trial name
- NCT04800094
- Testing
- Investigational Liver Fat Quantification Software
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Pediatric ALL
GlideScope Spectrum Video Laryngoscope Blades and Stylet for Use in Neonate & Pre-Adolescent Populations
The overall purpose of this study is to assess the functionality \& impact of the use of the newly designed GlideScope Spectrum pediatric video laryngoscope and stylet for the orotracheal intubation of neonates and pediatric…
- Trial name
- NCT04836338
- Testing
- orotracheal intubation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Verathon
Blood Loss, Surgical
Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants
The objective of this study is to assess the safety and immunogenicity of recombinant thrombin (rThrombin) administered as an aid to hemostasis during burn wound excision and skin grafting in pediatric patients, newborn through…
- Trial name
- NCT00859547
- Testing
- rThrombin, 1000 IU/mL
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- ZymoGenetics
Ametropia, Myopia; Refractive Error
The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit.
The goal of this clinical trial is to evaluate the performance of a photorefraction screener in terms of sensibility, sensitivity and accuracy on children aged 3 to 8 y.o.
- Conditions
- Ametropia, Myopia; Refractive Error, Myopia; Astigmatism
- Trial name
- NCT06882408
- Testing
- Photorefraction device under investigation, Comparator device, Tabletop auto-refractometer, Comparator device, portable photorefraction device
- Where
- 2 sites in France
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Essilor International
Epilepsy
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
Study to evaluate the efficacy of Lacosamide (LCM) administered in addition to 1 to ≤3 other Anti-Epileptic Drugs in subjects with epilepsy ≥4 years to <17 years of age who currently have uncontrolled partial onset seizures.
- Trial name
- NCT01921205
- Testing
- Lacosamide
- Where
- 118 sites in United States, Argentina and 26 more
- Volunteers
- 404 people
- Sponsor
- UCB Pharma
Lennox Gastaut Syndrome (LGS)
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
The aims of the study are: to learn if soticlestat, when given as add-on therapy, reduces the number of major motor drop seizures in children, teenagers, and adults with Lennox-Gastaut Syndrome.
- Trial name
- NCT04938427
- Testing
- Soticlestat
- Where
- 98 sites in United States, Australia and 16 more
- Volunteers
- 270 people
- Sponsor
- Takeda
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
- Trial name
- NCT01596400
- Testing
- granisetron transdermal system, Granisetron IV
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Asthma
Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population
The objective of this study is to compare asthma-related exacerbations (emergency department (ED) or inpatient (IP) visit) and related cost in pediatric patients aged 4-11 years that received either fluticasone propionate 44 mcg…
- Trial name
- NCT01328964
- Testing
- Fluticasone propionate, Budesonide, Montelukast
- Volunteers
- 9,906 people
- Sponsor
- GlaxoSmithKline
Mixed Hearing Loss, Single-Sided Deafness
Osia 2 Pediatric Expansion Study
The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or…
- Conditions
- Mixed Hearing Loss, Single-Sided Deafness, Conductive Hearing Loss
- Trial name
- NCT05000931
- Testing
- Osia 2 System
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cochlear
Rhinitis, Allergic, Perennial
Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.
The primary objective of this study is to characterize, as accurately as possible, the estimation of the difference in pre-pubescent growth velocities between subjects treated continuously for one year with FFNS 110mcg QD, the…
- Trial name
- NCT00570492
- Testing
- Fluticasone furoate nasal spray
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 474 people
- Sponsor
- GlaxoSmithKline
Clostridium Difficile-associated Diarrhea (CDAD)
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
The purpose of this study was to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules in pediatric participants with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- SUNSHINE (NCT02218372)
- Testing
- Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid
- Where
- 44 sites in United States, Belgium and 8 more
- Volunteers
- 148 people
- Sponsor
- Astellas Pharma Europe B.V.
Postoperative Nausea and Vomiting
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
The primary objective of this study is to evaluate the efficacy of a single palonosetron IV dose compared to a single ondansetron IV dose in the prevention of postoperative nausea and vomiting through 24 hours after surgery in…
- Trial name
- NCT01395901
- Testing
- Palonosetron, Ondansetron
- Where
- 44 sites in United States, Argentina and 6 more
- Volunteers
- 670 people
- Sponsor
- Helsinn Healthcare SA
Plaque Psoriasis
Plaque Psoriasis Study in Pediatric Subjects
The purpose of this study is to compare the safety, efficacy and calcium metabolism of up to 8 weeks of treatment with calcitriol 3 mcg/g ointment versus its vehicle, when used twice daily, without occlusion, to treat children…
- Trial name
- NCT02186665
- Testing
- calcitriol ointment
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 19 people
- Sponsor
- Galderma R&D
Active Juvenile Psoriatic Arthritis
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
- Trial name
- PEAPOD (NCT04804553)
- Testing
- Apremilast
- Where
- 44 sites in Belgium, France and 12 more
- Volunteers
- 60 people
- Sponsor
- Amgen